script.reportAU
Women's health

Mifepristone and misoprostol

Brand: MS-2 Step

PBAC's latest decision on Mifepristone and misoprostol: Recommended with restriction (2023). Considered for Termination of an intrauterine pregnancy of up to 63 days of gestation.

PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2013
Submissions
3
2013 → 2023

Eligible population

Females of childbearing age with an intrauterine pregnancy of up to 63 days of gestation.

Therapy area
Women's health
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
surgical termination of pregnancy (STOP)
Economic model
Cost-minimisation
Eligible patients/year
29,511
ICER note
This is a Category 3 minor submission requesting a change in authority type from Authority Required (Telephone) to Authority Required (STREAMLINED). No economic evaluation was conducted; no ICER calculated. The submission is not eligible for cost-effectiveness assessment.

Submission history

Similar precedents

Open on full dashboard →